Article

Staged angioplasty for carotid artery stenosis to prevent postoperative hyperperfusion.

Department of Neurosurgery, Graduate School of Medicine, Gifu University, Gifu, Japan. s- yoshi@gifu- u.ac.jp
Neurosurgery (Impact Factor: 2.53). 04/2009; 64(3 Suppl):ons122-8; discussion ons128-9. DOI: 10.1227/01.NEU.0000334046.41985.BB
Source: PubMed

ABSTRACT Hyperperfusion (HP) is a rare but potentially devastating complication after carotid revascularization. This report describes the clinical efficacy of staged angioplasty (SAP) for carotid artery stenosis to prevent HP after carotid revascularization.
Eighteen of 143 patients with high-grade internal carotid artery stenosis scheduled for angioplasty were considered at high risk of postprocedure HP based on their severely impaired cerebral blood flow (CBF) and cerebral vasoreactivity, which were determined using single-photon emission computed tomography with acetazolamide. Nine of the high-risk patients were treated with carotid artery stenting and the other 9 were treated with SAP, which consisted of balloon angioplasty with undersized balloon catheters (Stage 1) followed by carotid artery stenting 1 to 2 months later (Stage 2).
In the regular carotid artery stenting group, 5 of 9 patients (56%) showed HP phenomenon on single-photon emission computed tomography just after stenting, and 1 patient (11%) developed status epilepticus owing to HP. In the SAP group, none of the 8 patients treated by SAP or the 1 patient who required stent placement during the first stage owing to a wall dissection developed postprocedure HP phenomenon or HP syndrome.
SAP decreased the HP phenomenon on single-photon emission computed tomography after performing these procedures in selected patients. Although additional intervention is needed, SAP is considered a relatively simple and effective method to avoid HP in patients at high risk of HP after carotid revascularization.

0 Bookmarks
 · 
98 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the feasibility and efficacy of angioplasty and stenting for symptomatic occlusion of carotid artery. From December 2004 to June 2009, 17 patients with progressive or reoccurred ischemic stroke or repeated transient ischemic attack resulted from the total occluded carotid artery underwent angioplasty and stenting were reviewed. All patients with successful procedure were followed up. Clinic and angiography data were documented prospectively. The median time from symptoms onset to procedure was 23 days (range 3-94 days). Twelve of the 17 patients (70%) were obtained technique success. Eight patients were observed the collapse of internal carotid artery between occluded location to origin of ophthalmic artery after the occlusion was patent. Two patients had clots which were solved with urokinase. The collapsed internal carotid artery was improved markedly in the compute tomography angiograph 7 days after the procedure. No any complications related procedures occurred. One patient died from myocardial infarct and one suffered from ischemic minor stroke in brainstem for a median follow-up of 346.5 days. One of 9 patients (11.1%) was observed in-stent stenosis in the follow-up angiography. Angioplasty and stenting was a potential alternative therapy for symptomatic occlusion of carotid artery. Further study is required to determine the safety of this treatment.
    Journal of Thrombosis and Thrombolysis 04/2010; · 1.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intracranial stenting is increasingly used as an add-on to medical therapy despite the fact that the overall clinical benefit remains a matter of debate, since we lack results of randomized trials. Decision making on interventional treatment is made on the grounds of the anticipated risk of stroke with antiplatelet medication on one hand and on the experience with stent treatment based on data from case series and registries on the other hand. This review will summarize the current knowledge on both topics serving as the fundament of patient selection for intracranial stenting. A second objective is to highlight some specific problems that are encountered when treating patients interventionally. Procedure-related complication rates and rates of in stent stenoses are still too high to be confident that endovascular treatment is superior to medical therapy of symptomatic stenoses. Optimization of patient selection criteria, stent technology, and periprocedural management are necessary to become undoubtedly competitive with antiplatelet therapy. With the current stage of development, interventional treatment of intracranial stenoses should be confined to specialized centers with a high expertise in neurovascular procedures.
    Neuroradiology 03/2010; 52(7):633-44. · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND AND PURPOSE: We conducted a large retrospective survey of the clinical results of carotid artery stenting (CAS) for about 10 years performed by neurointerventionists at 43 Japanese institutions. Hence, the historical perspective of CAS in Japan was demonstrated. METHODS: Cases were stratified into three separate periods based on the approval status of devices: the first period, in which off-label CAS was performed using balloon protection; the second period, using a limited number of approved devices under filter protection; the third period, using appropriate protection selected from several different options based on the preoperative evaluation (tailored CAS). Clinical results were retrospectively evaluated. Then 30-day results of each period were examined. The major adverse event (MAE) was defined as stroke, myocardial infarction or death. RESULTS: Between January 2001 and December 2010, a total of 8,092 cases were registered, including 4,072, 1,526 and 2,494 in the first, second and third period, respectively. In the first period, 92 % of CAS was performed under balloon protection. In contrast, 91 % was done under filter protection in the second period. In the third period, various protection methods were used, including balloon (31 %), filter (50 %) and proximal protection (18 %). The rate of MAE at 30 days was 6.1 %, 10.2 % and 3.5 % in the first, second and third periods, respectively, and 6.3 % in all periods combined. The rate of MAE in the third period was significantly lower than that in the first and second periods. CONCLUSIONS: The historical paradigm of CAS in Japan was demonstrated. Due to the improvement of devices, increasing experience and appropriate selection of protection, CAS is continuing to evolve into a safer and more efficacious method of stroke prevention.
    Acta Neurochirurgica 10/2012; · 1.55 Impact Factor